Mazdutide tracker
Educational reference for Mazdutide. Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
175 h
Tmax
48 h
Category
glp1
Also known as: IBI362, LY3305677
> PLACEHOLDER — pending clinical review by licensed pharmacist. Mazdutide is an investigational GLP-1 / glucagon dual agonist in clinical development for weight loss. Not FDA-approved. Subcutaneous injection.
Mechanism
An investigational dual GLP-1 and glucagon receptor agonist. In research the combined activity is hypothesized to address appetite and glycemia (GLP-1) alongside increased energy expenditure (glucagon).
Research summary
Investigational and not FDA-approved. It has been studied for weight management and type 2 diabetes, with trials reported particularly in China. Larger-scale evaluation continues per the literature.
Dosing in the literature
Trials have evaluated once-weekly subcutaneous administration under study protocols. There is no approved regimen; this summary does not provide dosing.
Reported side effects
Gastrointestinal effects are the most commonly reported in trials, consistent with the incretin class. Given glucagon activity, metabolic parameters are monitored. The full safety profile is not yet established.
Stacking notes
As an investigational compound, combination use is confined to study settings. General incretin considerations apply.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- Mazdutide (IBI362 / LY3305677) clinical trials · peer-reviewed clinical trials (2023)search PubMed for mazdutide; investigational
- GLP-1/glucagon dual agonist reviews · peer-reviewed review articles (2023)investigational; not FDA-approved
Track Mazdutide in TrackPep
Reconstitution calculator, interactive body-map rotation, side-effect timeline, weight trends, and a private log — all in one place. Free to try.